Gilead has seven candidates in the pipeline for the treatment of HCV infection.
Gilead acquired Pharmasset in 2011 for $11 billion to gain the company's lead HCV candidate PS-7977, now called sofosbuvir or GS-7977, which is a nucleotide NS5B inhibitor. Gilead's lead candidate GS-7977 is being studied
extensively in Phase II and III studies in genotype 1, 2, and 3 infected patients in combination with ribavirin, with or without pegylated interferon.
The company expects to file a new drug application (NDA) for the treatment of genotype 2
and 3 patients in 2013.
The complete article - New Second Generation Combination Therapy For HCV - First Or Best In The Market (Part 1),is available here.
Gilead acquired Pharmasset in 2011 for $11 billion to gain the company's lead HCV candidate PS-7977, now called sofosbuvir or GS-7977, which is a nucleotide NS5B inhibitor. Gilead's lead candidate GS-7977 is being studied
extensively in Phase II and III studies in genotype 1, 2, and 3 infected patients in combination with ribavirin, with or without pegylated interferon.
The company expects to file a new drug application (NDA) for the treatment of genotype 2
and 3 patients in 2013.
The complete article - New Second Generation Combination Therapy For HCV - First Or Best In The Market (Part 1),is available here.
FONTE:
http://hepatitiscnewdrugresearch.com/-2013-sofosbuvir-gs-7977.html
TRADUÇÃO:
http://translate.google.com/translate?sl=en&tl=pt&js=n&prev=_t&hl=pt-PT&ie=UTF-8&eotf=1&u=http%3A%2F%2Fhepatitiscnewdrugresearch.com%2F-2013-sofosbuvir-gs-7977.html
Nenhum comentário:
Postar um comentário